Tag: Sanofi
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.
Sanofi Presses Court Battle with Mylan in Appeal of EpiPen Antitrust...
With billions at stake, Sanofi ups the ante with Mylan in their EpiPen suit.
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
Sanofi Seeking Billions from Mylan in EpiPen Antitrust Suit
Sordid details of anticompetitive behavior alleged in court filing.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Study scheduled to commence next week.
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate
The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
